Multi-Targeted Antithrombotic Therapy for Total Artificial Heart Device Patients

Area of Science:

• Cardiovascular Surgery
• Hematology
• Medical Device Technology

Background:

• Patients with total artificial hearts (TAH) face high risks of thrombotic and bleeding complications.
• Current anticoagulation strategies require careful management to balance efficacy and safety.

Purpose of the Study:

• To outline the development and evaluate the outcomes of a multi-targeted antithrombotic clinical procedure guideline (CPG) for TAH patients.
• To assess the effectiveness of the CPG in managing anticoagulation and preventing adverse events.

Main Methods:

• A literature review of TAH anticoagulation informed the CPG design, incorporating multiple pharmacological agents.
• Thromboelastograph (TEG) and platelet light-transmission aggregometry (LTA) were used to monitor anticoagulation in 13 TAH patients.
• Blood loss and TEG/LTA values were tracked on postoperative days 1, 3, 7, and 14.

Main Results:

• The CPG was implemented, and anticoagulation management was adjusted based on TEG and LTA monitoring.
• Bleeding events, particularly high on postoperative days 1-3, were significantly reduced by day 7.
• Thrombus formation and thromboembolic events were prevented throughout the 2-week monitoring period.

Conclusions:

• The multidisciplinary, multi-targeted anticoagulation CPG successfully maintained adequate antithrombotic therapy in TAH patients.
• The guideline demonstrated efficacy in reducing bleeding while preventing thrombotic complications.
• This approach achieved acceptable hemostasis and improved patient safety post-TAH implantation.